As of 30 Sep 2025, 5 institutional investors reported holding $23,363,000 in principal (par value) of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | $23,363,000 | $18,818,473 | +$3,637 | 81.68% | 5 |
| 2025 Q2 | $23,363,000 | $17,787,228 | 76.2% | 5 | |
| 2025 Q1 | $23,363,000 | $17,777,468 | 76.14% | 5 | |
| 2024 Q4 | $23,363,000 | $18,181,290 | -$20,400 | 77.82% | 5 |
| 2024 Q3 | $23,363,000 | $17,535,188 | +$1,520,000 | 77.0% | 6 |
| 2024 Q2 | $21,363,000 | $13,668,131 | -$77,759,875 | 64.58% | 5 |
| 2024 Q1 | $150,514,494 | $93,853,240 | -$11,660,030,655 | 54.23% | 11 |
| 2023 Q4 | $170,334,654 | $86,027,205 | +$10,888,753 | 50.0% | 11 |
| 2023 Q3 | $147,861,853 | $107,719,810 | $0 | 63.55% | 11 |
| 2023 Q2 | $147,861,853 | $113,578,343 | -$1,434,414 | 67.75% | 11 |
| 2023 Q1 | $176,607,744 | $150,781,059 | +$336,553 | 77.1% | 11 |
| 2022 Q4 | $156,785,126 | $129,257,105 | -$509,968 | 75.89% | 9 |
| 2022 Q3 | $91,436,126 | $83,805,000 | -$1,736,671 | 80.81% | 8 |
| 2022 Q2 | $101,168,000 | $78,757,000 | -$54,523,725 | 72.95% | 10 |
| 2022 Q1 | $162,090,700 | $148,357,000 | +$2,013,200 | 83.87% | 18 |
| 2021 Q4 | $160,572,700 | $144,179,000 | -$1,121,637 | 81.73% | 18 |
| 2021 Q3 | $164,135,700 | $134,001,000 | -$2,602,411 | 75.26% | 17 |
| 2021 Q2 | $164,030,000 | $178,652,000 | +$5,057,388 | 100.3% | 17 |
| 2021 Q1 | $162,027,500 | $178,795,000 | -$13,557,562 | 103.64% | 13 |
| 2020 Q4 | $179,096,000 | $224,321,000 | +$2,415,769 | 125.81% | 13 |
| 2020 Q3 | $177,079,000 | $212,808,000 | -$7,312,413 | 119.66% | 13 |
| 2020 Q2 | $179,579,000 | $254,017,000 | +$147,150 | 140.38% | 16 |
| 2020 Q1 | $179,427,000 | $258,267,000 | -$1,674,298 | 143.96% | 14 |
| 2019 Q4 | $180,346,000 | $258,276,000 | +$258,275,897 | 143.0% | 17 |